Windlas Biotech Ltd

Windlas Biotech Ltd

Windlas Biotech Ltd has announced a schedule of analyst/institutional investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015. The meetings will be held virtually on September 7, 2026, and will cover publicly available documents. No unpublished price sensitive information (UPSI) will be shared during the meeting.

Windlas Biotech Ltd

Windlas Biotech Ltd reported Q1 FY27 earnings with revenue of INR248 crores, a 18% Y-o-Y growth, driven by diversified business model, operational excellence, and customer trust. The company completed a buyback of INR47 crores and declared a dividend of INR13 crores.

Windlas Biotech Ltd

Windlas Biotech Ltd has uploaded the audio recording of its Q1 conference call on its website, as per SEBI listing regulations.

Windlas Biotech Ltd

Windlas Biotech Ltd reported its Q1 FY27 financial results, with revenue of Rs 248 crores, a growth of 18% YoY, and adjusted EBITDA of Rs 34 crores, a growth of 26% YoY. The company also completed a Rs 47 crore share buyback and paid a dividend of Rs 13 crores.

Windlas Biotech Ltd

Windlas Biotech Ltd has announced its Q1 FY27 investor presentation, highlighting its growth trajectory, operational excellence, and diversified business model. The company reported its highest-ever quarterly revenue of ₹248 crore, representing an 18% YoY growth.

Windlas Biotech Ltd

Windlas Biotech Ltd has announced its unaudited standalone financial results for the quarter ended June 30, 2026, with revenue from operations at ₹2,480.99 crore and total income at ₹2,532.12 crore.

Windlas Biotech Ltd

Windlas Biotech Ltd has announced its unaudited standalone financial results for the quarter ended June 30, 2026, with revenue from operations at ₹2,480.99 crore and a net profit of ₹123.19 crore.

Windlas Biotech Ltd

Windlas Biotech Ltd has scheduled a conference call to discuss its financial performance for the quarter ended June 30, 2026, on August 11, 2026, at 11:30 A.M. IST.

Windlas Biotech Ltd

Windlas Biotech Ltd schedules conference call to discuss Q1FY27 financial performance on August 11, 2026, at 11:30 P.M. IST.

Windlas Biotech Ltd

Windlas Biotech Ltd has scheduled a board meeting on August 10, 2026, to consider and approve the unaudited standalone financial results for the quarter ended June 30, 2026. The trading window is closed from July 1, 2026, and will reopen after the expiry of 48 hours from the date of declaration of the financial results.

Windlas Biotech Ltd

Windlas Biotech Ltd submitted the combined voting results and scrutinizer's report under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the 25th Annual General Meeting held on July 23, 2026. All resolutions were passed with the requisite majority. The company declared a final dividend of Rs. 6.30 per equity share for the financial year 2025-26 and appointed a new director in place of Mr. Hitesh Windlass, who is liable to retire by rotation.

Windlas Biotech Ltd

Windlas Biotech Ltd has submitted the combined voting results and scrutinizer's report for its 25th Annual General Meeting held on July 23, 2026. The report reveals that all resolutions were passed with the requisite majority. The company's financial statements for the financial year ended March 31, 2026, were approved, and a final dividend of Rs. 6.30 per equity share for the financial year 2025-26 was declared. The appointment of a director in place of Mr. Hitesh Windlass, Managing Director, was also approved.

Windlas Biotech Ltd

Windlas Biotech Ltd held its 25th Annual General Meeting on July 23, 2026, through video conferencing. The meeting was attended by 63 members, and the resolutions related to the adoption of audited financial statements, declaration of final dividend, appointment of directors, ratification of cost auditor remuneration, and appointment of an independent director were passed. The voting results will be placed on the company's website and stock exchange websites.